Groupe la Francaise Has $3.25 Million Stake in Qiagen N.V. $QGEN

Groupe la Francaise lowered its stake in Qiagen N.V. (NYSE:QGEN) by 37.0% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 83,911 shares of the company’s stock after selling 49,250 shares during the quarter. Groupe la Francaise’s holdings in Qiagen were worth $3,252,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Danske Bank A S bought a new position in Qiagen during the third quarter worth $36,000. Manchester Capital Management LLC bought a new stake in Qiagen in the fourth quarter valued at $42,000. Global Retirement Partners LLC increased its stake in Qiagen by 279.9% in the fourth quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock valued at $52,000 after purchasing an additional 851 shares in the last quarter. Hilltop National Bank acquired a new position in shares of Qiagen during the second quarter valued at about $50,000. Finally, Advisory Services Network LLC acquired a new position in shares of Qiagen during the third quarter valued at about $64,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Price Performance

QGEN stock opened at $43.36 on Tuesday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.31 and a current ratio of 2.85. The business has a 50-day simple moving average of $41.98 and a two-hundred day simple moving average of $40.30. The company has a market capitalization of $8.94 billion, a P/E ratio of 22.22, a price-to-earnings-growth ratio of 4.33 and a beta of 0.63. Qiagen N.V. has a 52-week low of $32.53 and a 52-week high of $57.81.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, topping the consensus estimate of $0.60 by $0.02. The firm had revenue of $535.04 million during the quarter, compared to the consensus estimate of $527.50 million. Qiagen had a return on equity of 14.47% and a net margin of 19.49%.The company’s quarterly revenue was up .2% compared to the same quarter last year. During the same period in the prior year, the business posted $0.60 earnings per share. Qiagen has set its FY 2026 guidance at 2.430- EPS. Research analysts expect that Qiagen N.V. will post 2.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. JPMorgan Chase & Co. raised their target price on Qiagen from $45.00 to $50.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Morgan Stanley upgraded Qiagen from an “overweight” rating to an “overweight” rating and increased their price target for the stock from $40.00 to $42.00 in a report on Tuesday, June 23rd. Barclays set a $40.00 price objective on Qiagen and gave the company an “equal weight” rating in a research note on Friday, August 7th. Stifel Nicolaus set a $40.00 price objective on Qiagen in a report on Friday, August 7th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Qiagen in a research report on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, Qiagen presently has a consensus rating of “Hold” and an average price target of $43.93.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.